Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00291109 · ClinicalTrials.gov registry record
An Examination of Predictors of Indicators of Response to Letrozole 2.5 mg
A clinical trial of Breast Cancer, sponsored by University of Kansas.
- Completed
- Registry status
- 40
- Enrollment target
- 1
- Study location
NCT00291109 is a study of Breast Cancer that has completed, run by University of Kansas. The registered enrollment target is 40 participants, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT00291109, a study of Breast Cancer, has completed, sponsored by University of Kansas.
- COMPLETED
- Registry status
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
To assess the quantitative real time PCR results of oligonucleotide probes for a number of gene transcription products that may be useful as predictors or indicators of response to letrozole
Conditions Studied
Interventions
- DRUG letrozole 2.5 mg
Study Locations (1)
Kansas
- University of Kansas Medical Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2003-01 |
| Est. Completion | 2005-07 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00291109
The ClinicalTrials.gov registry entry for NCT00291109 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,803-participant average among 1,224 other Breast Cancer trials with a reported enrollment target (99% lower). The listed sponsor is University of Kansas, which has 66 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which letrozole 2.5 mg is the first listed.
NCT00291109 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.
Frequently Asked Questions
What is clinical trial NCT00291109 about?
NCT00291109 is a clinical study titled "An Examination of Predictors of Indicators of Response to Letrozole 2.5 mg". To assess the quantitative real time PCR results of oligonucleotide probes for a number of gene transcription products that may be useful as predictors or indicators of response to letrozole
What is the current status of trial NCT00291109?
This trial is currently completed. The enrollment target is 40 participants. The study started on 2003-01. Estimated completion is 2005-07.
What conditions does trial NCT00291109 study?
This clinical trial studies the following conditions: Breast Cancer.
What interventions are being tested in trial NCT00291109?
The interventions under investigation include: letrozole 2.5 mg (DRUG).
Who is sponsoring clinical trial NCT00291109?
This trial is sponsored by University of Kansas, which has 66 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00291109 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Surviving Daily Life
RECRUITING
-
Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
RECRUITING
-
UNC Pleural Fluid Registry
RECRUITING
-
Harnessing Analysis RNA Expression and Molecular Subtype to Optimize Novel TherapY MBCA
RECRUITING · NA
-
Post-operative Radiotherapy Omission in Selected Patients With Early Breast Cancer Trial International VErsion (PROSPECTIVE)
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.